For those with major depression, there is a new treatment option - one that offers hope when patients are not responding to existing treatment. The ...
PHOENIX (AZFamily) — A ketamine-derived nasal spray is now available for the millions of Americans living with severe ...
The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.
Boing Boing on MSN12d
FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with itOn Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...
Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...
In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.
Q4 2024 Earnings Conference Call January 22, 2025 8:00 AM ETCompany ParticipantsJessica Moore - Vice President, ...
Hosted on MSN14d
FDA approves first nasal spray treatment for severe depressionThe FDA approved Johnson & Johnson’s Spravato nasal spray as a stand-alone treatment for patients suffering from severe depression. It is now the first-ever stand-alone therapy for treatment-resistant ...
Spravato is a first-of-its-kind medication to help manage treatment-resistant depression, according to the pharmaceutical company. The nasal spray can be given to people who haven’t seen ...
WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback